POLICY BRIEFINGS


Responses to Ways and Means Request for SGR Reform Ideas


Several physician groups have responded to House Ways and Means Committee Chairman Dave Camp’s request for solutions to the current problems presented by the sustainable growth rate formula under the Medicare physician payment system.  The AMA urged Congress to: waive program integrity laws and regulations for physicians who seek to engage in and lead innovative delivery models that promote quality, increase coordination and reduce costs; extend anti-trust protections under the Medicare Shared Savings Program to other providers pursuing innovative contracting arrangements with payers; and help make sure that physicians engaged in new models of care delivery are not precluded from having a meaningful market presence with hospitals and insurers.  Also, the Medical Group Management Association suggested that Congress: prevent CMS from backdating penalties under the electronic health record meaningful use requirements and encourage CMS to be more flexible in allowing physicians to experiment with new payment models for delivering and reimbursing health care (such as bundled payments, partial capitation, ACOs, medical homes and other hybrid approaches).


CMS Actuaries Provide New Medicare Projections


The CMS Office of the Actuary released a new set of projections on future Medicare spending which differ from the projections released earlier under the 2012 Medicare Trustee Reports.  Stating that the Trustee report projections are unrealistic, e.g. because it was assumed the 31% reduction in physician payment rates would not be waived as has always been the case in the past, the OA said that (1) Medicare Part B costs will increase to 1.87% of GDP by 2020 and 3.58% of GDP by 2080 (assuming SGR cuts are prevented) in contrast to the increases under the Trustee report (i.e. costs increasing to 1.65% of GDP by 2020 and 2.52% of GDP by 2080); and (2) Medicare Part A costs will increase to 9.9% of GDP in 2085 which is 3.6 percentage points higher than shown under the Trustees’ report.


Republicans Criticize PPACA Educational Funding


After HHS awarded a $20 million contract to a public relations firm to implement a national campaign to provide education on PPACA initiatives to prevent illness, Republicans criticized the Administration for its so-called election year “propaganda” moves.


Grants for Family Health Information Centers


HHS announced that $4.9 million in grants will be made available to help fund Family-to-Family Health Information Centers supporting care for children with special health needs.


FDA User Fee Reauthorizations Move Forward


As stated above, the Senate sent to the House its version of FDA user fee legislation which: reauthorizes at $693 million for FY 2013 the Prescription Drug User Fee Act (PDUFA); reauthorizes at $595 million for FY 2013 the Medical Device User Fee Act (MDUFA); creates new user fee programs for generic drugs ($299 million for FY 2013-2017) and biosimilar drugs; ensures that named-brand drugs are made available for generic testing; enhances penalties for drug counterfeiting; helps alleviate drug shortages; requires HHS to issue a report on a proposed regulatory framework with respect to medical device regulation and health information technology software prior to issuing final guidance on medical mobile applications; and modernize the FDA inspection process for foreign manufacturing facilities.  

During consideration of S. 3187 the following amendments were adopted: Harkin amendments to modify and limit certain exemptions to the Freedom of Information Act and to facilitate the development of recommendations on interoperability standards to inform and facilitate the exchange of prescription information across state lines; a Coburn/Burr amendment to require an independent assessment of the FDA review of drug applications; and a Portman/Schumer amendment to amend the Controlled Substances Act to place synthetic drugs in Schedule I; an amendment which provides whistleblower protections to uniformed employees of the public health service working at FDA; a provision which ensures that adequate information is disseminated to health care providers and payers about the potential benefits and risks of medical products on all patient populations, particularly underrepresented subpopulations, including racial subgroups; a provision which deals with sunscreen testing and labeling; a provision which sets out deadlines for the issuance of certain regulations and to require a GAO report on the implementation of the clinical trial registration and reporting requirements under the Public Health Service Act; a provision which requires the FDA commissioner to report to Congress on issues with respect to small businesses; and another which amends the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.  

The CBO estimated that the Senate bill would reduce the Federal deficit by $363 million over ten years.  The House bill is expected to be changed before final passage to also be revenue neutral or deficit reducing.  In general, the House bill, H.R. 5651, includes the following: the Food and Drug Administration Reform Act of 2012; the Biosimilar User Fee Act of 2012; the Generic Drug User Fee Amendments of 2012; the Medical Device User Fee Amendments of 2012; and the Prescription Drug User Fee Amendments of 2012.



May 28, 2012: | Page 1 Page 2 Page 3

SERVICES




BRIEFING ARCHIVE


 -  2018


 +  2017


 +  2016


 +  2015


 +  2014


 +  2013


 +  2012


 +  2011